Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsNA

The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction

Sponsor: University of Oxford

NCT ID: NCT05878912

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Diet intervention (other)
How long the study runs
Study runs about 47 months (dates as stated)
About the drug or intervention
Diet intervention — other: The diet intervention delivers a weight loss program.
Patient visit burden
"The person's quality of life and how much they can exercise Participants will attend 2 study visits, separated by 3-6 months." (as stated by sponsor)
Type of study
Testing a treatment
Ages
18 Years to 85 Years
Who
All
Number of participants
120
Started
2023-01-20
Last checked
2024-04

Plain English Summary

What is this study?

  • • Testing a new treatment for heart failure with preserved ejection fraction
  • • NA - 120 participants
  • • This study looks at the effects of weight loss in people who have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese

Who can take part?

  • • Ages 18 Years to 85 Years
  • • Diagnosed with heart failure with preserved ejection fraction

Where?

  • • Oxford - Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

This study looks at the effects of weight loss in people who have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese. The main questions it aims to answer are whether weight loss in this group of people improves: 1. The heart's shape, how well it pumps blood and how well it uses fuels 2. The person's quality of life and how much they can exercise Participants will attend 2 study visits, separated by 3-6 months. The intervention period takes place in between the 2 study visits. Each study visit will involve measurements including: * Symptom and quality of life questionnaires * Body measurements such as height and weight * Blood tests * Ultrasound scans of the heart (echocardiogram) * Magnetic Resonance Imaging (MRI) scans of the heart * Exercise components during the scans * 6 minute walk test Participants are randomly allocated (in other words, by lottery) to either 'diet' or 'control' groups. The control group will continue standard care. The diet group will be enrolled in a weight loss program supervised by the study team. Participants in the diet group will replace their usual meals with meal replacement products specifically designed to deliver a low calorie diet for weight loss. The products will consist of formula soups, shakes and porridges. This diet would last 8 weeks, followed by a guided period of food reintroduction and maintenance.

More detail

An interim analysis is planned at 60 recruits to review the recruitment target.

Heart Failure With Preserved Ejection FractionObesity

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years - 85 Years
  • Who can join: All genders

What the study is looking for

  • ✓Heart failure with preserved ejection fraction (HFpEF)
  • ✓Left ventricular ejection fraction (LVEF) =/\> 50%
  • ✓Body Mass Index (BMI) approximately =/\> 27.5 kg/m\^2

Who cannot take part

  • ✗Contraindications to magnetic resonance imaging
  • ✗NYHA class IV
  • ✗Significant valvular, ischemic, infiltrative or other potentially confounding heart disease
  • ✗Pregnancy, planned pregnancy or lactating
  • ✗Any other conditions which may potentially compromise the safety or scientific validity of the study
See the full criteria
Inclusion Criteria: * Heart failure with preserved ejection fraction (HFpEF) * Left ventricular ejection fraction (LVEF) =/\> 50% * Body Mass Index (BMI) approximately =/\> 27.5 kg/m\^2 Exclusion Criteria: * Contraindications to magnetic resonance imaging * NYHA class IV * Significant valvular, ischemic, infiltrative or other potentially confounding cardiac disease * Pregnancy, planned pregnancy or lactating * Any other conditions which may potentially compromise the safety or scientific validity of the study

Where Is This Study? (1 UK site)

Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital

Oxford OX3 9DU, United Kingdom

Recruiting
Site contact (verified)
Oliver Rider, DPhilPrincipal Investigator

How to Get in Touch

Jiliu Pan, BMBCh

Sponsor contact

CONTACT

+44(0)1865234591 jiliu.pan@cardiov.ox.ac.uk

Jenny Rayner, DPhil

Sponsor contact

CONTACT

+44(0)1865221172 jenny.rayner@cardiov.ox.ac.uk
Data sourced from ClinicalTrials.gov · Last verified: 2024-04